Cardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica
View original at globenewswire.comCardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica Chicago, Jan…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
MANIFEST-17K study reported a 0% rate of esophageal damage and pericardial tamponade rate of just 0.36%
80% confidenceChina accounted for 22.26% of the global cardiovascular disease burden
80% confidenceThe therapeutics & surgical devices category held a commanding position, accounting for a 77.5% revenue share in 2025
80% confidenceVascular device investment reaching USD 759 million and cardiovascular venture investment stabilizing at USD 542 million in 2024
80% confidenceFDA listed 1,176 devices in its Breakthrough Device Program as of August 2024, with 243 designations specifically allocated to cardiovascular innovations
80% confidenceNew clinical trial initiations surged by 68% in the decade ending 2024
80% confidenceBoston Scientific's Farapulse procedures finished in under 90 minutes in 90% of cases, while thermal ablation only achieved this speed in 60% of cases
80% confidenceThe global cardiovascular devices market size was valued at USD 74.58 billion in 2025 and is projected to hit the market valuation of USD 157.32 billion by 2035 at a CAGR of 7.70% during the forecast period 2026–2035
80% confidenceAverage cost for a TAVR procedure in 2024 ranged from USD 52,176 in Chicago to USD 81,889 in California
80% confidenceUS market for smart wearable ECG monitors was valued at USD 586.91 million in 2024
80% confidenceMedical tourism options for TAVR in India were priced at approximately USD 14,500 in 2024
80% confidenceTotal US cardiovascular deaths hit 931,578 with age-adjusted death rate rose to 233.3 per 100,000
80% confidence127.9 million US adults had some form of cardiovascular disease in 2024
80% confidenceWeekly procedure rates averaging 16,200 cases throughout 2024 for pulsed field ablation
80% confidenceAs of December 2025, over 2,000 cardiovascular drugs and device-delivery therapies were in active development
80% confidenceVaripulse achieved an 80% recurrence-free rate
80% confidenceFDA cleared a record 39 new clinical AI algorithms in May 2025, bringing the total to 116 cleared cardiology algorithms
80% confidenceNearly 12.1 million people in the US are projected to be diagnosed with Atrial Fibrillation by 2030
80% confidenceProjected global healthcare cost savings from wearable adoption estimated at USD 200 billion over the next 25 years
80% confidenceGlobal shipments of wearable health devices reached 440 million units in 2024, with 160 million units specifically designated as medical sensors for clinical monitoring
80% confidenceTotal surgical procedure volumes reached 18.9 million in 2024, with the United States and China accounting for 3.6 million and 3.5 million interventions, respectively
80% confidenceUK cardiac waiting list swelling to 421,433 patients by May 2024 and Canadian wait times reaching 194 days
80% confidenceStroke caused 162,890 deaths in the US
80% confidenceFDA cleared 16 distinct breakthrough cardiovascular devices in the 12 months leading up to August 2024
80% confidenceThe US supported 4,300 operational cardiac catheterization labs in 2024, while the number of hybrid cath labs globally reached 2,400
80% confidence92% of US smartwatch users utilize their device primarily for health tracking, with 37% specifically monitoring heart metrics
80% confidenceFunding for AI-integrated cath lab solutions rose by 20% in 2024
80% confidenceTriClip patients were 28% less likely to be hospitalized for heart failure and 90% of TriClip patients saw regurgitation reduction
80% confidenceA 2025 analysis identified 51 major cardiovascular clinical trials published between 2019 and 2024, enrolling a total of 292,985 patients
80% confidenceMedtronic's PulseSelect demonstrated an average skin-to-skin procedure time of just 36 minutes in 2024 with 98% of pulmonary veins remained isolated
80% confidence
Data points we hold from this source
| U.S. Food and Drug Administration · cardiology ai algorithms total | 116 algorithms |
| U.S. Food and Drug Administration · ai algorithms cleared may 2025 | 39 algorithms |
| U.S. Food and Drug Administration · cleared breakthrough cvd devices 12mo | 16 devices |
| U.S. Food and Drug Administration · breakthrough cardiovascular devices | 243 devices |
| U.S. Food and Drug Administration · breakthrough devices total | 1176 devices |